2025-521702-18-00RecruitingPhase 1
A phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-DFC413 and safety and imaging properties of [68Ga]Ga-NNS309 in patients with solid tumors
Source: EU CTIS (euclinicaltrials.eu) · Last updated 15 Sept 2026
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 62 (estimated)
- First submitted
- 15 Oct 2025
- Start date
- 21 May 2026
- Lead sponsor
- Novartis Pharma AG
- Diseases
- Sarcoma, Pancreatic cancer, Lung cancer, Colorectal cancer, Metastatic breast cancer, Triple-negative breast cancer
- EU CT number
- 2025-521702-18-00
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 62
- 10 sites in 5 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (10)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Universitaetsklinikum Essen (AoR) | Essen | Germany | Recruiting |
| Rigshospitalet | Copenhagen Oe | Denmark | Recruiting |
| Odense University Hospital | Odense C | Denmark | Recruiting |
| Hospital Universitari Vall d'Hebron | Barcelona | Spain | Not yet recruiting |
| Institut Catala D'oncologia | L'Hospitalet de Llobregat | Spain | Not yet recruiting |
| Centre Leon Berard | Lyon | France | Recruiting |
| Institut Paoli-Calmettes | Marseille | France | Recruiting |
| Oncopole Claudius Regaud | Toulouse | France | Recruiting |
| CHRU De Nancy | Vandoeuvre Les Nancy Cedex | France | Recruiting |
| Instituto Portugues de Oncologia do Porto Francisco Gentil, E.P.E. | Porto | Portugal | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.